Related Experiment Video

Updated: Jul 26, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Surgical ventricular restoration and other surgical approaches to heart failure

Patrick I McConnell1, Robert E Michler

  • 1Division of Cardiothoracic Surgery, N847 Doan Hall, 410 W. 10th Avenue, Columbus, OH 43210, USA.

Current Heart Failure Reports
|July 23, 2005
PubMed

Insights

New surgical options, including coronary artery bypass and surgical ventricular restoration, are being explored for ischemic congestive heart failure (CHF). These advanced treatments aim to improve outcomes for patients with end-stage heart disease.

Area of Science:

  • Cardiovascular Surgery
  • Heart Failure Research
  • Regenerative Medicine

Background:

  • Historically, surgical intervention for ischemic congestive heart failure (CHF) was limited.
  • Advancements now include new surgical procedures and assist devices for end-stage CHF.

Purpose of the Study:

  • Evaluate coronary artery bypass efficacy in ischemic CHF patients versus medical therapy.
  • Assess the added benefit of surgical ventricular restoration (SVR) in dilated hearts undergoing revascularization.

Main Methods:

  • Review of the Surgical Treatment for Ischemic Heart Failure (STICH) trial.
  • Examination of novel surgically deployed devices for ventricular support.
  • Review of cellular cardiomyoplasty techniques, including stem cell transplantation.

Main Results:

  • The STICH trial investigates coronary artery bypass versus medical management.
  • Surgical ventricular restoration is assessed for additional benefits.
  • New devices and cellular therapies show promise in augmenting ventricular performance.

Conclusions:

  • Surgical interventions and innovative therapies are expanding treatment options for ischemic CHF.
  • Ongoing research and clinical trials are crucial for advancing care in end-stage heart failure.

More Related Videos

Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...